B Group, Inc. 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
B Group, Inc. disclosed 17 US equity positions worth $104.6m in its Q3 2025 13F filing. The largest position was ADMA at 33.8% of the reported book, followed by ZLAB and AKERO THERAPEUTICS INC. Against the Q2 2025 filing, it opened 2 new positions, added to 4 and reduced 3 among the top 17 holdings.
What did B Group, Inc. own in Q3 2025? Top 17 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ADMA ADMA BIOLOGICS INC | Healthcare | 33.8% | $35.4m | 2,412,542 | 4% | added |
| 2 | ZLAB ZAI LAB LTD | Healthcare | 13.0% | $13.6m | 400,000 | 0% | held |
| 3 | AKERO THERAPEUTICS INC | 10.6% | $11.0m | 232,446 | 0% | held | |
| 4 | CLLS CELLECTIS S A | 8.9% | $9.4m | 3,281,501 | 1% | added | |
| 5 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 5.6% | $5.9m | 1,800,556 | 0% | held |
| 6 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 4.3% | $4.5m | 175,706 | -7% | reduced |
| 7 | NRX PHARMACEUTICALS INC | 4.3% | $4.5m | 3,000,000 | – | new | |
| 8 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 3.9% | $4.1m | 135,000 | 23% | added |
| 9 | AURA AURA BIOSCIENCES INC | 3.4% | $3.5m | 572,576 | 0% | held | |
| 10 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 3.1% | $3.3m | 1,500,000 | 0% | held |
| 11 | SGHT SIGHT SCIENCES INC | 3.1% | $3.2m | 930,000 | 0% | held | |
| 12 | SYRE SPYRE THERAPEUTICS INC | 1.6% | $1.7m | 100,000 | 25% | added | |
| 13 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.6% | $1.7m | 31,500 | -10% | reduced |
| 14 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.4% | $1.4m | 75,000 | 0% | held |
| 15 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.3% | $1.4m | 35,000 | 0% | held |
| 16 | GAME GAMESQUARE HLDGS INC | 0.2% | $169.7k | 250,000 | – | new | |
| 17 | INSM INSMED INC | Healthcare | 0.0% | $22.8k | 158 | -100% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.